가금류 의약품 시장 : 동물 유형별, 제품별, 질병 유형별, 투여 경로별, 지역별 - 예측(-2029년)

The poultry medicine/pharmaceuticals market is projected to reach USD 6.68 billion by 2029 from USD 5.01 billion in 2024, at a CAGR of 5.9% during the forecast period. The increasing consumption of poultry and its products from the developing countries is mainly responsible for the growth of poultry medicine/pharmaceuticals market as it results in increased poultry farming practices. The rise in illnesses in poultry, especially Newcastle disease and Coccidiosis, leads to the need for vaccines, antibiotics, and immune boosters. Also, the growing attention towards food safety and the reduction of antibiotics, has made many farms to resort to alternative therapies such as probiotics and more effective vaccines. Furthermore, the growing rates of poultry production amongst developing countries increases the demand for efficacious medicine/pharmaceuticals, which contributes to the sustainable, safe and productive poultry keeping.

"By animal type, chickens segment is expected to have the largest market share in the poultry medicine/pharmaceuticals market."

Based on animal type, the chickens segment is expected to hold the largest market share in the poultry medicine/pharmaceuticals market. Owing to high domestic poultry consumption of protein sources like chicken meat and eggs. This increase in demand has contributed change in age to the poultry farming especially in developing areas with an increase in the production of chickens. Chickens are also commonly affected by several diseases; Newcastle disease, Infectious Bronchitis and Coccidiosis, which explains the use of vaccines, antibiotics and probiotics to enhance the health and productivity of the flocks Several factors attributed to increasing food production also explain the need for higher standards biologically and on farm bio-security interventions. Innovations in vaccine delivery methods such as in ovo vaccination have enhanced the efficiency and effectiveness of immunization on a large scale providing more avenues for consumption of poultry medicine/pharmaceuticals.

"By product, vaccine segment is expected to have the largest market share in the poultry medicine/pharmaceuticals market."

Based on product, the largest share of this market is vaccines since they are critical in the prevention of infectious diseases which can rapidly spread through large flocks, like Newcastle disease, Infectious Bronchitis, and Avian Influenza. Effective vaccination of a poultry flock ensures health, productivity, and minimization of losses due to eventual flock culling order by the veterinary authority. Regulatory pressure to lower the use of antibiotics makes vaccines a preferred choice in the management of diseases as they prevent infections without adding to antimicrobial resistance. Technology advancement, such as ovo vaccination, allows for efficient mass immunization; thus, vaccine administration has become practical and scalable to large poultry farms. In the context of disease prevention and sustainable farming practices, vaccines have cemented their position as the largest segment in the poultry medicine/pharmaceuticals market.

"By disease indication, newcastle disease segment is expected to have the largest market share in the poultry medicine/pharmaceuticals market."

Based on disease indication, the largest share of this market is newcastle disease since the disease affects the poultry worldwide and severely impacts poultry farmers economically. High mortality rates and losses in productivity due to outbreak required vaccination programmes; therefore, vaccines against Newcastle disease are indispensable in poultry health management. Second-generation recombinant and thermostable vaccines have helped increase the ease of use and thus their usage in countries with intensive poultry farming. The continued emphasis on disease prevention and government containment programs have made Newcastle Disease the largest category in the poultry medicine/pharmaceuticals market.

"By route of administration, oral segment is expected to have the largest market share in the poultry medicine/pharmaceuticals market."

Based on route of administration, The oral route of administration in poultry medicine/pharmaceuticals is efficient and convenient in the medication of large flocks in comparison to the other routes as it delivers medication through either water or feed, thereby getting an equal amount of dose delivery to all birds without time-consuming and stressful individual birds' handling. The oral route is most suited for antibiotics, vaccines, probiotics, and vitamins and therefore used in a very diversified preventive and therapeutic mode of application. Labor cost-cutting, simplification in dosing, and accommodation in large-scale poultry systems where quick effective management of disease is important make this route highly acceptable. Given the practicality and economies of scale involved in oral delivery, this mode forms the mainstay in the poultry farming business and commands the market for medicine/pharmaceuticals.

"By region, North America region is expected to have the largest market share in the poultry medicine/pharmaceuticals market."

The poultry medicine/pharmaceuticals market is dominated by North America as a result of advanced poultry farming systems prevalent in the region, high poultry products intake, and greater concern for biosecurity and disease control. The region is characterized by existing legislation that encourages responsible antibiotic use and as a consequence drive producers to vaccines and other health solutions in the production of food. Continuous investments in research and development as well as modern technologies put in place for the management and therapy of diseases further promotes upward movement of this market. On top of that, due to the fact that there is a growing need for sustainable as well as high-yield systems of poultry rearing, the production of medicines that assist in maintaining flocks health and productivity has increased in the region thereby further entrenching North America's market leader position.

A breakdown of the primary participants (supply-side) for the poultry medicine/pharmaceuticals market referred to for this report is provided below:

• By Company Type: Tier 1-35%, Tier 2-40%, and Tier 3-25%
• By Designation: C-level-20%, Director Level-35%, and Others-45%
• By Region: North America-27%, Europe-25%, Asia Pacific-30%, ROW-18%

Prominent players in the poultry medicine/pharmaceuticals market are are MSD (US), Elanco (US), Boehringer Ingelheim (Germany), Ceva Sante Animale (France), Zoetis Service LLC (US), Virbac (France), Phibro Animal Health (US), Hester Biosciences Limited (India), Meiji Animal Health (Japan), Venky's India (India), Bimeda Corporate (Ireland), Calier (Spain), Hipra (Spain), Vetanco (Argentina), Vaxxinova (Netherlands), Biovac Group (Israel), Kemin Industries (US), O.L.KAR Agrozoovet Service (Ukraine), Indovax (India), Avimex (Mexico), Synthese Elevage (France), Provet Pharma Pvt Ltd (India), Huvepharma (Bulgaria), Romvac Company (Romania), and VMN Pharmaceuticals (Turkey).

Research Coverage:

The report analyzes the poultry medicine/pharmaceuticals market and aims at estimating the market size and future growth potential of this market based on various segments such as animal type, product, route of administration and region. The report also includes a competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall poultry medicine/pharmaceuticals market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

• Analysis of key drivers (increasing poultry consumption, growing incidence of poultry diseases, advances in poultry medicine/pharmaceuticals, initiatives by government agencies and animal associations), restraints (high cost of vaccines development, antibiotic resistance concerns), opportunities (growth in emerging markets, industrialization of poultry farming), challenges (regulatory compliance)
• ZMarket Penetration: It includes extensive information on products offered by the major players in the global the poultry medicine/pharmaceuticals market. The report includes various segments in offering, application, end user and region.
• Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global poultry medicine/pharmaceuticals market.
• Market Development: Thorough knowledge and analysis of the profitable rising markets by offering, application, end user and region.
• Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global the poultry medicine/pharmaceuticals market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products, and capacities of the major competitors in the global poultry medicine/pharmaceuticals market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKETS & REGIONS COVERED
  • 1.3.1 YEARS CONSIDERED
  • 1.3.2 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 POULTRY PHARMACEUTICALS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: POULTRY PHARMACEUTICALS MARKET, BY PRODUCT AND COUNTRY (2023)
• 4.3 POULTRY PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 POULTRY PHARMACEUTICALS MARKET, BY REGION (2022-2029)
• 4.5 POULTRY PHARMACEUTICALS MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing poultry consumption
    • 5.2.1.2 Growing incidence of poultry diseases
    • 5.2.1.3 Advancements in poultry pharmaceuticals
    • 5.2.1.4 Favorable initiatives by government agencies & animal welfare associations
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of vaccine development
    • 5.2.2.2 Concerns associated with antibiotic resistance
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 High growth potential of emerging economies
    • 5.2.3.2 Industrialization of poultry farming
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory compliance for poultry pharmaceuticals
• 5.3 INDUSTRY TRENDS
  • 5.3.1 ANTIBIOTIC-FREE SOLUTIONS
  • 5.3.2 EMERGENCE OF INNOVATIVE VACCINE TECHNOLOGIES
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 TECHNOLOGY ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 mRNA vaccines
    • 5.6.1.2 Nanoparticle drug delivery
    • 5.6.1.3 CRISPR gene editing
  • 5.6.2 COMPLEMENTARY TECHNOLOGIES
    • 5.6.2.1 IoT-enabled health monitoring
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Automated drug delivery systems
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 THREAT OF SUBSTITUTES
  • 5.7.3 BARGAINING POWER OF SUPPLIERS
  • 5.7.4 BARGAINING POWER OF BUYERS
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.8 REGULATORY LANDSCAPE
  • 5.8.1 REGULATORY ANALYSIS
    • 5.8.1.1 US
    • 5.8.1.2 Europe
    • 5.8.1.3 Asia Pacific
    • 5.8.1.4 Latin America
    • 5.8.1.5 Middle East & Africa
  • 5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.8.2.1 North America
    • 5.8.2.2 Europe
    • 5.8.2.3 Rest of the World
• 5.9 PATENT ANALYSIS
  • 5.9.1 PATENT PUBLICATION TRENDS FOR POULTRY PHARMACEUTICALS
• 5.10 TRADE ANALYSIS
• 5.11 PRICING ANALYSIS
  • 5.11.1 AVERAGE SELLING PRICE TREND OF POULTRY PHARMACEUTICALS, BY REGION (2022-2024)
  • 5.11.2 AVERAGE SELLING PRICE OF POULTRY VACCINES, BY KEY PLAYER (2023)
• 5.12 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 BUYING CRITERIA
• 5.14 UNMET NEEDS AND END-USER EXPECTATIONS
  • 5.14.1 UNMET NEEDS
  • 5.14.2 END-USER EXPECTATIONS
• 5.15 ECOSYSTEM MARKET ANALYSIS
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: MARKET DEVELOPMENT IN NIGER DELTA (MADE)
  • 5.16.2 CASE STUDY 2: JOURNEY OF TRIBAL WOMEN
  • 5.16.3 CASE STUDY 3: PROBLEMS & PROSPECTS OF POULTRY FARMING IN CHITTOOR, ANDHRA PRADESH
• 5.17 ADJACENT MARKET ANALYSIS
• 5.18 INVESTMENT & FUNDING SCENARIO
• 5.19 IMPACT OF AI/GENAI ON POULTRY PHARMACEUTICALS MARKET

6 POULTRY PHARMACEUTICALS MARKET, BY ANIMAL TYPE

• 6.1 INTRODUCTION
• 6.2 CHICKEN
  • 6.2.1 BROILER
    • 6.2.1.1 Specifically bred for high meat yield to drive market
  • 6.2.2 LAYER
    • 6.2.2.1 Growing demand for eggs to fuel market
• 6.3 TURKEY
  • 6.3.1 CONSUMER PREFERENCE FOR ORGANIC TURKEY BY-PRODUCTS TO DRIVE MARKET
• 6.4 DUCK
  • 6.4.1 GROWING FOCUS ON DEVELOPMENT OF TARGETED VACCINES FOR DVH TO FUEL UPTAKE
• 6.5 OTHER POULTRY

7 POULTRY PHARMACEUTICALS MARKET, BY PRODUCT

• 7.1 INTRODUCTION
• 7.2 DRUGS
  • 7.2.1 ANTIBIOTICS
    • 7.2.1.1 Most widely used drug in poultry management to drive market
  • 7.2.2 ANTIPARASITICS
    • 7.2.2.1 Ability to combat against coccidiosis and ectoparasites to boost demand
  • 7.2.3 ANTISEPTICS
    • 7.2.3.1 Maintainance of biosecurity through infection reduction to fuel uptake
  • 7.2.4 NUTRITIONALS
    • 7.2.4.1 Optimization of poultry health with enhanced productivity to support market growth
  • 7.2.5 OTHER DRUGS
• 7.3 VACCINES
  • 7.3.1 LIVE-ATTENUATED VACCINES
    • 7.3.1.1 Cost-efficiency and high efficacy benefits to fuel uptake
  • 7.3.2 INACTIVATED VACCINES
    • 7.3.2.1 Pathogen carriers with high stability to drive market
  • 7.3.3 RECOMBINANT VACCINES
    • 7.3.3.1 Ability to combat several avian diseases to boost demand
  • 7.3.4 OTHER VACCINES
• 7.4 FEED ADDITIVES
  • 7.4.1 ADDITIONAL INCORPORATION TO DIETS FOR ENHANCED BENEFITS TO SUPPORT MARKET GROWTH

8 POULTRY PHARMACEUTICALS MARKET, BY DISEASE TYPE

• 8.1 INTRODUCTION
• 8.2 NEWCASTLE DISEASE
  • 8.2.1 INNOVATIONS IN NEXT-GEN VACCINES TO PROPEL MARKET
• 8.3 INFECTIOUS BRONCHITIS
  • 8.3.1 HIGH MORTALITY CASES TO BOOST DEMAND
• 8.4 INFECTIOUS BURSAL DISEASE
  • 8.4.1 GROWING DEMAND FOR MULTIVALENT VACCINES TO FUEL MARKET
• 8.5 COCCIDIOSIS
  • 8.5.1 DEVELOPMENT OF ANTI-COCCIDIAL DRUGS TO FUEL UPTAKE
• 8.6 SALMONELLA
  • 8.6.1 INCREASING INCIDENCE OF SALMONELLA OUTBREAKS TO DRIVE MARKET
• 8.7 MAREK'S DISEASE
  • 8.7.1 GROWING FOCUS ON ENSURING FLOCK PRODUCTIVITY TO SUPPORT MARKET
• 8.8 OTHER DISEASES

9 POULTRY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION

• 9.1 INTRODUCTION
• 9.2 ORAL ROUTE OF ADMINISTRATION
  • 9.2.1 HIGH UPTAKE OF ANTIBIOTICS DUE TO SCALABILITY AND COST-EFFICIENCY TO DRIVE MARKET
• 9.3 INJECTABLE ROUTE OF ADMINISTRATION
  • 9.3.1 RAPID TREATMENT RESPONSE TO FUEL MARKET
• 9.4 TOPICAL ROUTE OF ADMINISTRATION
  • 9.4.1 UPTAKE OF ANTIPARASITIC TREATMENT TO SUPPORT MARKET GROWTH
• 9.5 OTHER ROUTES

10 POULTRY PHARMACEUTICALS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Stringent regulatory protocols for disease prevention to drive market
  • 10.2.3 CANADA
    • 10.2.3.1 Growing focus on animal health to drive market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Growing awareness of poultry health issues in Germany
  • 10.3.3 UK
    • 10.3.3.1 Growing focus on antibiotic-free poultry to boost demand
  • 10.3.4 FRANCE
    • 10.3.4.1 Avian influenza outbreaks and disease prevention strategies to fuel market growth
  • 10.3.5 SPAIN
    • 10.3.5.1 Increased poultry production and export to drive market
  • 10.3.6 ITALY
    • 10.3.6.1 Rising poultry trade and biosecurity measures to drive market
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 JAPAN
    • 10.4.2.1 Focus on biosecurity and innovative pharmaceutical products to drive market
  • 10.4.3 CHINA
    • 10.4.3.1 Increasing incidence of avian influenza to boost demand
  • 10.4.4 INDIA
    • 10.4.4.1 Rapid expansion of poultry farming to fuel uptake
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Growing focus on advanced pharmaceuticals to support market
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Frequent outbreak of coccidiosis to support market growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Surge in poultry export to fuel uptake
  • 10.5.3 MEXICO
    • 10.5.3.1 Increasing investments in broiler genetics to propel market
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Expanding poultry sector to fuel uptake
  • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POULTRY PHARMACEUTICALS MARKET
• 11.3 REVENUE ANALYSIS, 2019-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Region footprint
    • 11.5.5.3 Animal type footprint
    • 11.5.5.4 Product footprint
    • 11.5.5.5 Disease indication footprint
    • 11.5.5.6 Route of administration footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
  • 11.7.1 FINANCIAL METRICS
  • 11.7.2 COMPANY VALUATION
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES & APPROVALS
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS
  • 11.9.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 MERCK ANIMAL HEALTH (SUBSIDIARY OF MERCK & CO., INC.)
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 MnM view
      • 12.1.1.3.1 Key strengths
      • 12.1.1.3.2 Strategic choices
      • 12.1.1.3.3 Weaknesses & competitive threats
  • 12.1.2 ELANCO
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Deals
      • 12.1.2.3.2 Expansions
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product approvals
      • 12.1.3.3.2 Deals
      • 12.1.3.3.3 Expansions
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 CEVA SANTE ANIMALE
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 MnM view
      • 12.1.4.3.1 Key strengths
      • 12.1.4.3.2 Strategic choices
      • 12.1.4.3.3 Weaknesses & competitive threats
  • 12.1.5 ZOETIS SERVICES LLC
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Deals
      • 12.1.5.3.2 Expansions
      • 12.1.5.3.3 Other developments
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 VIRBAC
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Deals
  • 12.1.7 PHIBRO ANIMAL HEALTH CORPORATION
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 HESTER BIOSCIENCES LIMITED
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Deals
  • 12.1.9 MEIJI ANIMAL HEALTH CO, LTD. (SUBSIDIARY OF K.M BIOLOGICS CO. LTD.)
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 VENKY'S INDIA
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
  • 12.1.11 BIMEDA CORPORATE
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
  • 12.1.12 CALIER
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
  • 12.1.13 HIPRA
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
  • 12.1.14 VETANCO
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
  • 12.1.15 VAXXINOVA INTERNATIONAL BV
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
  • 12.1.16 BIOVAC GROUP
    • 12.1.16.1 Business overview
    • 12.1.16.2 Products offered
  • 12.1.17 KEMIN INDUSTRIES, INC.
    • 12.1.17.1 Business overview
    • 12.1.17.2 Products offered
  • 12.1.18 O.L.KAR.-AGROZOOVET-SERVICE
    • 12.1.18.1 Business overview
    • 12.1.18.2 Products offered
  • 12.1.19 INDOVAX
    • 12.1.19.1 Business overview
    • 12.1.19.2 Products offered
  • 12.1.20 AVIMEX
    • 12.1.20.1 Business overview
    • 12.1.20.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 SYNTHESE ELEVAGE
  • 12.2.2 PROVET PHARMA PRIVATE LIMITED
  • 12.2.3 HUVEPHARMA
  • 12.2.4 ROMVAC COMPANY S.A.
  • 12.2.5 VMN PHARMACEUTICALS

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS